Looks like the management are looking to the long-term to knock back an offer from Pfizer! That alone would rerate this stock being a big pharma. But conversely for Pfizer to make an offer must mean they expect Scenesse to do well so kudos to Wolgren and the rest of the CUV board to go it alone and retain most of the upside.
To have the amount of shares on issue they do when EMA approval has taken this long is testament to running a relatively tight ship. I know fingersdk mentioned that they did do a consolidation awhile back but I still think the level of dilution is impressive.
I noticed revenues from Dec quarter to Mar quarter have doubled ie $400+k to $800+k. It looks like they are gaining traction.
I think 2017 will be a good year ie. profitable and cash flow positive which should rerate the stock even further.
CUV Price at posting:
$4.90 Sentiment: Buy Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)